Arthritis and rheumatoid arthritis can be cured. Early diagnosis and proper treatment help relieve pain for patients.
New York, NY (PRWEB) March 17, 2007
U.S. supplement manufacturer Vitaloix Laboratories will make its much anticipated foray into the Chinese marketplace in late 2007, having appointed XPD Pharma as the distributor for its Flexcerin™ supplement. Flexcerin™ has already established a successful consumer presence in both the North American and European marketplaces. In a press release made available on Wednesday, the company said the product, which is designed to promote healthy mobile joint function and connective tissue, will be distributed under the co-promotion agreement of both parties. The company said that this distribution agreement for China will be for an initial period of two years, but could then be extended by mutual agreement.
Recent statistical data shows that more than 355 million people in the world suffer from arthritis and rheumatoid arthritis, and China has over 100 million. Tang Fulin, a rheumatoid arthritis professor at Beijing College Hospital, said 98 percent of people will get the disease when they get older. However, he said, "Arthritis and rheumatoid arthritis can be cured. Early diagnosis and proper treatment help relieve pain for patients."
The joint health category has been a busy place in the last couple of years, since the Vioxx scandal caused consumers to cast about for side-effect-free natural alternatives to prescription medicines.
"The launch of this therapeutic breakthrough into China brings a new option to those millions of people that suffer from chronic joint pain at some time in their lives. We are pleased to introduce Flexcerin™ to them. The product has already been widely used by joint pain sufferers worldwide. Joint pain strikes people of all ages and activity levels, and if not properly treated or dealt with, typically gets progressively worse. With concerns rising in the medical field recently about the heart disease dangers of several prescription medications, many people are looking for a safe alternative to deal with joint pain and Flexcerin™ is more than capable to deal with that that challenge," said Kelly McRae, a spokesperson for Vitaloix.
XPD is focusing its marketing efforts on China because it is one of the fastest growing OTC markets in the world. New legislative initiatives and the accelerating pace of development in the Chinese retail pharmacy sector also substantiate the expectations for growth.
Available now, you can learn more about Flexcerin™ through the website http://www.Flexcerin.info.
# # #